| Disease Domain | Count |
|---|---|
| Infectious Diseases | 5 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 4 |
| Monoclonal antibody | 1 |
| Top 5 Target | Count |
|---|---|
| ATP | 2 |
| Kv1.3(Voltage-gated potassium channel subunit Kv1.3) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Kv1.3 blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date10 Mar 2025 |
Sponsor / Collaborator |
Start Date20 Sep 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
withaferin A derivatives 2-19 compound 16(Universidad de La Laguna) ( ATP ) | Leishmaniasis More | Preclinical |
withaferin A derivatives 2-19 compound 14(Universidad de La Laguna) ( ATP ) | Leishmaniasis More | Preclinical |
Thymol anysoate (9) | Leishmaniasis More | Preclinical |
Anti-KCNA3 antibody (Integral Molecular) ( Kv1.3 ) | Giardiasis More | Preclinical |
Compound 6(Universidad de La Laguna) | Leishmaniasis More | Preclinical |





